About Us
About us
Company Profile
About Yuxin Pharmaceutical
Pragmatic and innovative—building a healthier future together.
A specialized, cutting-edge pharmaceutical company in the greater health sector.
Sichuan Yuxin Pharmaceutical Co., Ltd. was founded in 1995 with a registered capital of 17.78 million yuan. The company is currently located at No. 51, West Section of Changjiang Road, South Area, Shifang Economic Development Zone, covering a site area of 140 mu. It successfully obtained the domestic pharmaceutical GMP certification in June 2016.
The company employs a total of 170 people, including 20 engineers and pharmacists, as well as 40 technical staff. Throughout its development, the company has consistently earned numerous prestigious awards over the years, earning titles such as "Advanced Collective," "Advanced Enterprise for Technological Transformation and Expansion," "Key Leading Enterprise," "One of Sichuan Province's Top 100 Fastest-Growing SMEs," "Sichuan Province's Little Giant Enterprise," and "Specialized, Fine, and Novel Enterprise." Additionally, in 2019 and 2020, the company was honored with the titles "Deyang City Technology Center," "Sichuan Provincial Enterprise Technology Center," and "Sichuan Provincial High-Tech Enterprise," respectively.
Yuxin was founded in
Registered capital
Company employees
Technical personnel
Phase One Project
The first-phase project has a total investment of 120 million yuan. Upon completion, it will include: - A synthesis workshop equipped with a 3-ton/year Vitamin D2 production line and a 3-ton/year Vitamin D3 production line. - A comprehensive extraction workshop featuring: - One standardized Scutellaria baicalensis glycoside (Baicalin) production line with an annual capacity of 80 tons; - One 150-ton/year berberine hydrochloride production line; - One 80-ton/year rutin production line; - One 10-ton/year andrographolide production line; - One 10-ton/year puerarin production line; - One 50,000-ton/year traditional Chinese medicine granule production line, including specific lines for: - Phellodendron bark granules (8,000 tons/year); - Scutellaria root granules (12,000 tons/year); - Sophora japonica flower buds granules (4,000 tons/year); - Pueraria root granules (9,000 tons/year); - Ginkgo leaf granules (3,000 tons/year); - Honeysuckle flower granules (4,000 tons/year); - Forsythia fruit granules (5,000 tons/year); - Andrographis paniculata granules (5,000 tons/year). All production lines are designed as standardized facilities that fully comply with GMP requirements.
Phase II Project
The second-phase project has a total investment of 40 million yuan (including 8 million yuan in working capital), occupies an area of 52,905 square meters, and features a total building footprint of 24,938 square meters—of which 17,049 square meters are dedicated to production workshops and storage facilities. Currently, the company has obtained both the **Veterinary Drug Production License** (License No.: (2022) Veterinary Drug Prod. Cert. No. 22151, covering production scopes such as granules made from traditional Chinese medicine extracts, as well as specific extracts like Scutellaria baicalensis extract, Andrographis paniculata lactone, Artemisia capillaris extract, Licorice Extract, Forsythia suspensa extract, Patchouli Oil, and Berberine Hydrochloride) and the **Veterinary Drug GMP Certificate** (Certificate No.: (2022) Veterinary Drug GMP Cert. No. 22015). To date, the company has secured approval numbers for 20 distinct veterinary drug products, including Scutellaria baicalensis extract, Andrographis paniculata lactone, Artemisia capillaris extract, Patchouli Oil, Licorice Extract, Forsythia suspensa extract, Berberine Hydrochloride, Banqing Granules, Jinhuanglianban Granules, Maxing Shigan Granules, Sanwei Kangqiu Granules, Sihuang Zhili Granules, Yinzhi Jiedu Granules, Gan Dan Granules, Licorice Granules, Jiebai Granules, Qiqing Baidu Granules, Qizhen Zengmian Granules, Wuwei Changqing Granules, and Shuanghuang Baidu Granules.
Phase III Project
The total investment for the Phase III project is 50 million yuan, with key construction components and scale including factory buildings, R&D facilities, and supporting infrastructure, totaling 21,000 m² of floor space. The project plans to establish five active pharmaceutical ingredient (API) production lines: 1. Lidocaine Hydrochloride Production Line; 2. Dehydrocholesterol Production Line; 3. Furosemide Production Line; 4. Diphenhydramine Hydrochloride Production Line; 5. Calamine Production Line. Upon completion, the project will achieve an annual production capacity of 20 tons of other anesthetic drugs, 4 tons of various vitamins and their derivatives, 2.5 tons of cardiovascular system medications, and 2.5 tons of antihistamine drugs, along with 100 tons of dermatological or topical pharmaceutical products.
Cultural Philosophy
Corporate Vision
Dedicated to becoming a specialized pharmaceutical company in the greater health sector—expert, focused, and highly respected by both employees and society.
Corporate Spirit
Stay humble, work efficiently, and remain honest and practical.
Development Philosophy
Rooted in talent, focused on specialization and professional services, we pursue steady growth.
Pharmaceutical Guidelines
Quality is the lifeblood of a company—strictly adhere to GMP standards and rigorously follow job-specific SOPs.
Contact Us
Company Address: No. 51, West Section of Changjiang Road, South Area, Shifang Economic Development Zone, Sichuan
Copyright ©2025 Sichuan Yuxin Pharmaceutical Co., Ltd. Power By：300.cn